Scientists discover an unexpected link between the well-known stress protein FKBP51, autophagy and the effectiveness of antidepressants
While depression is the most common psychiatric disease worldwide, only one third of the patients achieve sustained remission following treatment with currently available antidepressants. Scientists at the Max Planck Institute of Psychiatry in Munich have now unraveled a mechanism by which the stress-related protein FKBP51 affects antidepressant efficacy.
Many antidepressant drugs are only effective, when they interact with the stress-related protein FKBP51.
© MPI of Psychiatry / Isabella Wieser
In a combined interdisciplinary research approach working with cell cultures, mouse models and finally patient samples, the scientific team observed that FKBP51 acting together with antidepressants organizes intracellular complexes important for autophagy.
This intracellular process of “self-digestion” ensures efficient recycling of damaged material and has recently been linked to a range of different diseases. It could therefore serve as an effective target for novel antidepressant drugs and the implementation of personalized medicine.
The poor effectiveness of antidepressants is at least partially due to a lack in understanding of the mechanism of action of these drugs. The FK506 binding protein 51 (FKBP51) is a known regulator of stress-related receptors in the brain. It interacts with the so-called glucocorticoid receptor, thus influencing the stress hormone axis and stress physiology in general. Previous research at the Max Planck Institute of Psychiatry in Munich already provided a link between the genetic variants of FKBP51 and the efficacy of different antidepressants in patients.
Scientists around the group leaders Theo Rein and Mathias Schmidt have now unraveled the mechanism by which the protein FKBP51 affects antidepressant efficacy. The researchers found that FKBP51 orchestrates the composition and activity of protein complexes driving autophagy. Autophagy is an intracellular process of “self-digestion” that enables efficient recycling of damaged intracellular material, thereby ensuring cellular integrity and functioning. Autophagy has been established as a pivotal process in a range of (patho-) physiological conditions, including cancer, diabetes and more recently neurotransmission or neurodegeneration.
In the context of depression, the molecular actions of FKBP51 on autophagy synergize with those of antidepressants. “In cultured cells that do not express FKBP51, antidepressants could not elicit autophagy,” explains Nils Gassen. “Thus, FKBP51 sets the stage for antidepressants to act on the brain,” says Jakob Hartmann, together with Gassen first author of the current study.
Using mouse models, the researchers observed that missing FKBP51 largely abolished the effects of antidepressants on behavior and on autophagic markers. For example, treatment with the antidepressant paroxetine enhanced social behavior in stressed wildtype mice but not in those with deletion of FKBP51. To evaluate the clinical values of their findings, the team investigated the effects of FKBP51 in human blood cells. Protein analysis confirmed the correlation between the expression levels of FKBP51 and the levels of autophagy markers and FKBP51 was required for the effects of antidepressants on autophagic pathways. Treating cultivated blood cells from patients at the time of admission with antidepressants allowed prediction of the therapeutic outcome for the patient after six weeks.
“Taken together, our finding of FKBP51-dependent antidepressants’ effects on intracellular pathways, brain function and behavior strengthens the relevance of the genetic association of FKBP51 with antidepressant response, and furthermore substantiates the need for more targeted studies,” concludes Theo Rein. “Nevertheless, given the complexity of depression and the plethora of reported molecular effects of antidepressants, it is unlikely that all antidepressants, current or future, will depend on FKBP51 or any other single protein. Yet we suggest that autophagy-initiating mechanisms should be considered as a pharmacological target to improve the treatment of depression.”
Dr. Theo Rein
Project Group Leader
Max Planck Institute of Psychiatry, München
Phone: +49 89 30622-531
Dr. Anna Niedl
Press and Public Relations
Max Planck Institute of Psychiatry, München
Phone: +49 89 30622-263
Fax: +49 89 30622-370
Gassen NC, Hartmann J, Zschocke J, Stepan J, Hafner K, Zellner A, Kirmeier T, Kollmannsberger L, Wagner KV, Dedic N, Balsevich G, Deussing JM, Kloiber S, Lucae S, Holsboer F, Eder M, Uhr M, Ising M, Schmidt MV, Rein T.
Association of FKBP51 with Priming Autophagy Pathways and Mediating Antidepressant Treatment Response: Evidence in Cells, Mice and Humans.
PLOS Medicine, 11. November 2014
Dr. Theo Rein | Max-Planck-Institute
Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute
Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy